Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Healthequity (HQY) Research & Development (2016 - 2025)

Historic Research & Development for Healthequity (HQY) over the last 13 years, with Q4 2025 value amounting to $65.9 million.

  • Healthequity's Research & Development rose 951.5% to $65.9 million in Q4 2025 from the same period last year, while for Oct 2025 it was $256.8 million, marking a year-over-year increase of 1160.95%. This contributed to the annual value of $239.5 million for FY2025, which is 946.11% up from last year.
  • According to the latest figures from Q4 2025, Healthequity's Research & Development is $65.9 million, which was up 951.5% from $64.8 million recorded in Q3 2025.
  • In the past 5 years, Healthequity's Research & Development registered a high of $65.9 million during Q4 2025, and its lowest value of $32.3 million during Q1 2021.
  • Over the past 5 years, Healthequity's median Research & Development value was $54.0 million (recorded in 2023), while the average stood at $51.7 million.
  • In the last 5 years, Healthequity's Research & Development soared by 255.12% in 2021 and then soared by 4210.53% in 2022.
  • Healthequity's Research & Development (Quarter) stood at $38.1 million in 2021, then rose by 28.42% to $48.9 million in 2022, then rose by 13.75% to $55.6 million in 2023, then grew by 8.23% to $60.2 million in 2024, then rose by 9.52% to $65.9 million in 2025.
  • Its Research & Development was $65.9 million in Q4 2025, compared to $64.8 million in Q3 2025 and $61.4 million in Q2 2025.